The Next Level of Clinical Pharmacology
OUR FOCUS
We provide clinical and translational pharmacology expertise to improve drug and natural product development & clinical testing.
What are clinical and translational pharmacology?
Clinical pharmacology is the study of drugs in humans. In drug development, clinical pharmacologists focus on discovering optimal drug doses, regimens, and combinations for a particular disease. Clinical pharmacology incorporates solid understanding of patient variability (why some people respond differently to drugs), toxicology, drug metabolism, pharmacokinetics, and drug interactions. Translational pharmacology is an interdisciplinary field that incorporates data from a variety of sources (everything from cell studies to animal models of disease to real world data) to improve clinical drug development and medicine utilization.OUR SERVICES
Clinical Pharmacology
- Clinical protocol design
- Clinical pharmacology studies
- Pharmacokinetic/pharmacodynamic (PK/PD) analysis
- Dose selection
Pharmacometrics
- Development of mathematical models for PK/PD
- Extrapolation of preclinical data (in vitro and animal) to humans
Regulatory
- Support meetings with FDA and other health authorities
- Author clinical pharmacology components of regulatory documents
Verdient Science brings rigorous science and extensive knowledge of pharmacology to each client engagement. Our primary focus is on the quality and efficiency of new product development. We provide several additional services for researchers, media, health care providers, and investors. We have worked with everyone from small startups to large pharmaceutical companies.
WHO WE ARE
Verdient Science was founded by two Ph.D. pharmacologists with expertise in clinical and translational pharmacology. We have worked across various areas, such as neuroscience, oncology, immunology, and have specialized expertise in the study of Schedule 1 substances, such as cannabinoids and psychedelics.
Partners & Co-Founders
Linda Klumpers, Ph.D.
Linda has done clinical research and management consulting since 2006 and co-authored more than 15 peer-reviewed publications in the field of cannabinoids. She invented 2 patents.
Linda earned a M.Sc. in Neuroscience and a Ph.D. in Clinical Pharmacology of Cannabinoids in the Netherlands (see her thesis). She is a Dutch registered Clinical Pharmacologist.
Linda has been studying cannabinoids in humans for more than 17 years (see publications here), and received six honors and awards, including the BJCP Prize, handed out by the British Journal of Clinical Pharmacology. In 2020, she was granted €1.9mln (grant no. 848120001) for Medicinal Cannabis as a co-applicant (more information here).
She founded Tomori Pharmacology (DBA Cannify), a company that translates cannabinoid science into customized, educational tools for patients and clinicians.
Michael Tagen, Ph.D.
Mike has 20 years of research experience, including 15 years in clinical drug development in hospital, biopharmaceutical, and consulting settings. He has worked on over 50 clinical studies and co-authored 38 peer-reviewed publications.
Team
Jan Rozanc, Ph.D.
Scientific Consultant
Matthew Green, Ph.D.
Scientific Consultant
Jakub Mlost, Ph.D.
Scientific Consultant
In addition to our core team, we collaborate with an extensive network of experienced scientists to bring the right experts for any project. These include specialists in medicine, pharmacy, formulation chemistry, biostatistics, clinical trial operations, and regulatory science.
Our headquarters are in Denver, Colorado with additional offices in Miami Beach, Florida.
NEWS & RESOURCES
Poster Presentation by Verdient Science at ICRS 2024
Linda Klumpers and Mike Tagen from Verdient Science presented exciting research at the International Cannabinoid Research Society (ICRS) conference from June 30 – July 4,
Analysis of Human Laboratory Studies of High-Dose Oral Δ9-THC Published by Verdient Science
Hundreds of human laboratory studies of THC have been conducted. Although most studies of oral THC used a typical dose of around 10 mg, some
2023 Verdient Science Highlights
Throughout 2023, Verdient Science completed many exciting projects in various areas of pharmacology:
STAY CONNECTED
Enter your email for our newsletter about cannabinoid science and research.